Nano‐curcumin supplementation in patients with mild and moderate acute pancreatitis: A randomized, placebo‐controlled trial
Phytotherapy Research · 2023-11 · 37 (11) · 5279-5288
DOI: 10.1002/ptr.7958 ↗At a glance
Randomisierte kontrollierte Studie in Phytotherapy Research, published online on 2023-07-25. Written by Maedeh Chegini and 4 co-authors. Institution: Department of Clinical Nutrition, National Nutrition and Food Technology Research Institute, School of Nutrition and Food Technology, Shahid Beheshti…. Major MEDLINE topics: Curcumin, Pancreatitis. Cited 20 times so far (Crossref); 31 references. Funded by: National Nutrition and Food Technology Research Institute.
Abstract (original language)
We aimed to investigate whether nano‐curcumin as an anti‐inflammatory agent is effective in patients with mild and moderate AP. This study was a double‐blind, parallel‐arm randomized controlled trial conducted at Taleghani hospital, Tehran, Iran. Eligible subjects with a diagnosis of mild and moderate AP were randomly assigned to receive either two doses of nano‐curcumin (40 mg) or placebo (control) daily for 2 weeks. The primary endpoint was gastrointestinal (GI) ward length of stay (LOS). A total of 42 patients were randomly assigned to receive either nano‐curcumin ( n = 21) or placebo ( n = 21). Compared with placebo, nano‐curcumin supplementation decreased hospital LOS (RR = 0.67, 95% CI: 0.502–0.894; p = 0.006), reduced the need for analgesics over time (OR = 0.576, 95% CI: 0.421–0.790; p = 0.001), and increased overall appetite score over the study period ( β = 0.104, SE: 0.053; p = 0.049). No adverse effects or mortality were reported and there was no withdrawal during the study period. The results indicate that nano‐curcumin as an adjuvant therapy is safe and may reduce GI ward LOS, analgesics requirement, and improve the overall appetite in patients with mild and moderate AP. Future multi‐center trials with larger sample sizes are required to verify these findings. Clinical trial registration: www.ClinicalTrials.gov NCT04989166.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Nutrition, National Nutrition and Food Technology Research Institute, School of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ORCID profiles: Azita Hekmatdoost
Funding
- National Nutrition and Food Technology Research Institute
Cite
APA
Chegini, M., Sadeghi, A., Zaeri, F., Zamani, M., & Hekmatdoost, A. (2023). Nano‐curcumin supplementation in patients with mild and moderate acute pancreatitis: A randomized, placebo‐controlled trial. Phytotherapy Research, 37(11), 5279-5288. https://doi.org/10.1002/ptr.7958
Vancouver
Chegini M, Sadeghi A, Zaeri F, Zamani M, Hekmatdoost A. Nano‐curcumin supplementation in patients with mild and moderate acute pancreatitis: A randomized, placebo‐controlled trial. Phytotherapy Research. 2023;37(11):5279-5288. doi:10.1002/ptr.7958
BibTeX
@article{Chegini2023,
author = {Chegini, Maedeh and Sadeghi, Amir and Zaeri, Farid and Zamani, Majid and Hekmatdoost, Azita},
title = {Nano‐curcumin supplementation in patients with mild and moderate acute pancreatitis: A randomized, placebo‐controlled trial},
journal = {Phytotherapy Research},
year = {2023},
volume = {37},
number = {11},
pages = {5279--5288},
doi = {10.1002/ptr.7958}
}
EUVIMED